Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RASBURICASE Cause Intentional product use issue? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Intentional product use issue have been filed in association with RASBURICASE (Elitek). This represents 0.7% of all adverse event reports for RASBURICASE.

6
Reports of Intentional product use issue with RASBURICASE
0.7%
of all RASBURICASE reports
2
Deaths
5
Hospitalizations

How Dangerous Is Intentional product use issue From RASBURICASE?

Of the 6 reports, 2 (33.3%) resulted in death, 5 (83.3%) required hospitalization, and 1 (16.7%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RASBURICASE. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does RASBURICASE Cause?

Tumour lysis syndrome (116) Methaemoglobinaemia (92) Off label use (90) Product use in unapproved indication (76) Bacterial infection (75) Fungal infection (73) Cellulitis (72) Clostridium difficile colitis (72) Lymphoid tissue hypoplasia (72) Lymphopenia (72)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which RASBURICASE Alternatives Have Lower Intentional product use issue Risk?

RASBURICASE vs RAVULIZUMAB RASBURICASE vs RAVULIZUMAB-CWVZ RASBURICASE vs REBAMIPIDE RASBURICASE vs REBETOL RASBURICASE vs REBIF

Related Pages

RASBURICASE Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue RASBURICASE Demographics